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Abstract
Background: Transmissible gastroenteritis virus (TGEV) has a sialic acid binding activity that is believed to be
important for enteropathogenicity, but that has so far appeared to be dispensable for infection of cultured cells.
The aims of this study were to determine the effect of sialic acid binding for the infection of cultured cells under
unfavorable conditions, and comparison of TGEV strains and mutants, as well as the avian coronavirus IBV
concerning their dependence on the sialic acid binding activity.
Methods: The infectivity of different viruses was analyzed by a plaque assay after adsorption times of 5, 20, and 60
min. Prior to infection, cultured cells were either treated with neuraminidase to deplete sialic acids from the cell
surface, or mock-treated. In a second approach, pre-treatment of the virus with porcine intestinal mucin was
performed, followed by the plaque assay after a 5 min adsorption time. A student’s t-test was used to verify the
significance of the results.
Results: Desialylation of cells only had a minor effect on the infection by TGEV strain Purdue 46 when an
adsorption period of 60 min was allowed for initiation of infection. However, when the adsorption time was
reduced to 5 min the infectivity on desialylated cells decreased by more than 60%. A TGEV PUR46 mutant (HAD3)
deficient in sialic acid binding showed a 77% lower titer than the parental virus after a 5 min adsorption time.
After an adsorption time of 60 min the titer of HAD3 was 58% lower than that of TGEV PUR46. Another TGEV
strain, TGEV Miller, and IBV Beaudette showed a reduction in infectivity after neuraminidase treatment of the
cultured cells irrespective of the virion adsorption time.
Conclusions: Our results suggest that the sialic acid binding activity facilitates the infection by TGEV under
unfavorable environmental conditions. The dependence on the sialic acid binding activity for an efficient infection
differs in the analyzed TGEV strains.
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Background
Enveloped viruses enter their target cells by a two step
process [1]. The initial event is the attachment of the
virion to the cell surface. Subsequently, the viral envel-
ope fuses with the cellular membrane which enables the
viral genome to get access to the cytoplasm. The fusion
reaction may occur at the plasma membrane or, upon
endocytotic uptake of the virion, at the endosomal
membrane. The entry process requires the interaction of
o n eo rm o r ev i r a ls u r f a c ep r o teins with cellular recep-
tors. The binding to the cellul a rr e c e p t o rm e d i a t e st h e
attachment step and sets the stage for the subsequent
fusion process. Several viruses have developed a strategy
to recognize more than one surface structure of the tar-
get cell. The binding to some of these interaction part-
ners may not be sufficient for the virus to proceed to
the fusion step, but nevertheless it can support the entry
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actual cellular receptor.
TGEV is a porcine coronavirus that causes diarrhea in
pigs of all ages [2]. Piglets even die from the infection
unless they are protected by maternal antibodies. This
enveloped virus with a positive-stranded RNA genome
enters cells using the glycoprotein S for both attachment
to the cell surface and for fusion of the viral membrane
with the cellular membrane. The fusion activity of the S
protein is induced only after interaction with a specific
receptor on the surface of the target cell, porcine ami-
nopeptidase N (pAPN) [3]. The S protein is not only
able to bind to pAPN; it also has a sialic acid binding
activity with a preference for N-glycolylneuraminic acid
[4,5]. Interaction with sialylated macromolecules appears
to be dispensable for infection of cultured cells but is
believed to be important for the enteropathogenicity of
the virus [6,7]. This is based on the finding that a single
mutation in the S protein may result in the loss of both
the sialic acid binding activity and the enteropathogeni-
city, whereas the mutant viruses can be propagated in
cultured cells to the same titer as the parental virus
[7,8]. This finding has been explained by environmental
conditions in the intestine that make it more difficult
for a microorganism to initiate an intestinal infection
compared to an infection of cultured cells [9,10]. The
intestinal epithelium is covered not only by a glycocalix
layer but also by an even thicker layer of mucus [11]. As
mucins are rich in sialic acids, they are interaction part-
ners for TGEV and thus may help to penetrate the
mucus layer and to get access to pAPN on the surface
of the intestinal epithelial cells [9,10].
Results and discussion
Comparison of infectivities with and without
neuraminidase treatment
We tried to obtain experimental evidence for a role of
the sialic acid binding activity of TGEV in the infection
of cells under unfavorable conditions. For our analysis
we used the Purdue strain of TGEV which was grown
on swine testicular cells (ST) as described previously [5].
We analyzed the effect of desialylation of cells on infec-
tion by TGEV by a plaque assay [8]. In contrast to the
regular plaque assay a neuraminidase treatment prior to
infection was included to see a potential reduction in
the number of plaques. To evaluate the optimal experi-
mental setup, different neuraminidase concentrations
were included in the first analysis (0, 50, 125, 250, 500,
1000, 1500 mU/ml; data not shown). A concentration of
250 mU/ml resulted in a significant inhibition of TGEV
infection at an adsorption time of 5 min. As the cell cul-
ture appearance was not disturbed at this concentration,
we decided to use this neuraminidase concentration of
250 mU/ml for subsequent experiments. As higher
concentrations of the enzyme (up to 1.5 U/ml) gave no
increase in virus inhibition, we concluded that sialic
acids were removed to a satisfactory level. As shown in
Figure 1 (columns designated TGEV PUR46) and table
1, pre-treatment of cells with neuraminidase from Clos-
tridium perfringens, type V (250 mU/ml; Sigma) for 60
min reduced the infectivity of the parental virus by 26%
when the adsorption time was 60 min. When the virus
had only 5 min for adsorption, the infectivity on desialy-
lated cells was reduced by 64%. Infection at 20 min
adsorption time was in between these two values (reduc-
tion of 45%). This result is consistent with a previous
work where binding of virions rather than infectivity
was analyzed and where we have shown that desialyla-
tion of cultured cells reduces the binding of TGEV par-
ticles to these cells [5]. Our data indicate that the sialic
acid binding activity increases the efficiency of infection
at short adsorption times. This conclusion is supported
by the finding that no reduction was observed when the
hemagglutination deficient mutant HAD3 was subjected
to such an analysis (Figure 1, table 1). This mutant has
a point mutation in the S protein at position 209 (Leu-
Pro) and was selected because of its deficiency in sialic
acid binding [8]. Mutants m10 (deletion of 4 amino
acids at position 146-149), and m8 (point mutation at
amino acid 147) were analyzed in the same way for
adsorption times of 5 and 60 min [6,7]. In fact, with
these mutant viruses which are all deficient in sialic acid
binding activity, pre-treatment of cells with neuramini-
dase even increased the infectivity. This increase was
significant for mutants HA D 3a n dm 1 0w i t hap - v a l u e
below 0.05 (table 1). In a previous publication we con-
cluded that binding of the S protein to pAPN is even
more efficient after neuraminidase treatment as sialic
acid depletion on pAPN facilitates the protein binding
[5]. It is possible that this effect makes it is easier for
the mutants to get access to the cellular receptor pAPN
and to bind to the specific binding site after neuramini-
dase treatment of the cell culture. In contrast, in the
porcine intestine the binding of the mutants to pAPN
could be less efficient because of the presence of sialic
acids. For m8 and m10 it was reported that their entero-
pathogenicity is markedly reduced [6,7]. Therefore, a
less efficient binding to the cellular receptor pAPN in
vivo because of a deficiency in sialic acid binding could
be one explanation for this reduced enteropathogenicity.
To include another TGEV strain in our study we ana-
lyzed the Miller strain [12]. This strain was mainly pas-
saged in vivo, has an enteric and respiratory tropism
like the Purdue strain and is virulent in swine [12,13].
As shown in Figure 2 and table 1, the Miller strain
showed a reduction in infectivity after neuraminidase
pre-treatment of the cells. This reduction is in the same
range irrespective of the virion adsorption time (32%
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26% reduction for 60 min adsorption time).
Recently we have shown that infectious bronchitis
virus (IBV), an avian coronavirus, uses sialic acid as a
receptor determinant for infection of both cultured cells
and tracheal organ cultures [14,15]. We were interested
to know whether this virus also shows differences in the
dependence on the sialic acid binding activity at short
and long adsorption times. As shown in Figure 2 and
table 1, when analyzed in the same way as TGEV, the
Beaudette strain of IBV showed a reduction of the infec-
tivity after pre-treatment of cells with neuraminidase.
Similar to the result obtained with the Miller strain, the
reduction was irrespective of a long or short adsorption
time. After 60 min adsorption the infectivity of IBV was
reduced by 47% and after 5 min adsorption time it was
reduced by 33%. Taken together, our results indicate
that the Miller strain of TGEV rather resembles IBV
than the Purdue strain of TGEV as far as the sialic acid
dependence of infection is concerned.
Comparison of early and late infectivity
The infectious titer at three different time points (5, 20,
60 min) with and without neuraminidase treatment was
calculated. Figure 3 shows a mean value out of 4 differ-
ent experiments for TGEV PUR46, and HAD3, and out
of 3 different experiments for TGEV Miller. Highest
titers (2.27 × 10
7 PFU/ml at 5 min, 3.71 × 10
7 PFU/ml
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Figure 1 Sialic acid dependent infection by TGEV PUR46. The infectivity of parental virus (left columns) and the HAD3 mutant virus was
determined for adsorption times of 5, 20 or 60 min, respectively. The m8 and m10 mutant viruses were analyzed for adsorption times of 5 and
60 minutes. Prior to infection, ST cells were incubated for 60 min with either PBS (grey columns) or PBS containing 50 mU of neuraminidase
(white columns). All experiments were performed 4 times with standard deviations shown at the corresponding columns. Significant differences
are marked with an asterisk (*, p-value < 0.05).
Table 1 Infectivities of virus strains and mutants after
neuraminidase treatment of the cells
Virus adsorption time
5 min 20 min 60 min
TGEV PUR46 35.8% (*, 4) 55.0% (*, 4) 74.4% (4)
TGEV HAD3 149.1% (*, 4) 144.1% (*, 4) 130.7% (*, 4)
TGEV m8 98.8% (4) not determined 110.0% (4)
TGEV m10 119.9% (*, 4) not determined 109.3% (*, 4)
TGEV Miller 67.7% (*, 3) 76.9% (*, 3) 74.0% (*, 3)
IBV Beaudette 66.6% (*, 3) not determined 53.3% (*, 3)
The significance of the value is indicated by an asterisk, the number of
independent experiments used for calculation is indicated in brackets.
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Figure 2 Sialic acid dependent infection by IBV Beaudette and
TGEV Miller at short and long adsorption times. The infectivity
of IBV Beaudette and TGEV Miller was determined at adsorption
times of 5 or 60 min, respectively. Prior to infection, Vero cells (for
IBV) and ST cells (for TGEV) were incubated for 60 min with either
PBS (grey columns) or PBS containing 50 mU of neuraminidase
(white columns). The experiments were performed 3 times.
Standard deviations are indicated. Significant differences are marked
with an asterisk (*, p-value < 0.05).
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7 PFU/ml at 60 min) were
obtained for TGEV PUR46 that increased over time.
After neuraminidase treatment the titers decreased sig-
nificantly for the first two time points (8.13 × 10
6 PFU/
ml at 5 min, 2.06 × 10
7 PFU/ml at 20 min, and 7.33 ×
10
7 PFU/ml at 60 min). Infectious titers for the hemag-
glutination deficient mutant HAD3 were 5.14 × 10
6
PFU/ml at 5 min adsorption time, 2.05 × 10
7 PFU/ml at
20 min, and 3.64 × 10
7 PFU/ml at 60 min. After neura-
minidase treatment titers increased (9.30 × 10
6 PFU/ml
a t5m i n ,2 . 9 6×1 0
7 PFU/ml at 20 min, and 4.74 × 10
7
PFU/ml at 60 min). For the TGEV Miller strain infec-
tious titers in cell culture were more than 10fold lower
than for the TGEV Purdue strain (1.34 × 10
6 PFU/ml at
5 min, 2.09 × 10
6 PFU/ml at 20 min, 3.34 × 10
6 PFU/ml
at 60 min). After neuraminidase treatment the titers of
TGEV Miller decreased (9.08 × 10
5 PFU/ml at 5 min,
1.61 × 10
6 PFU/ml at 20 min, and 2.44 × 10
6 PFU/ml at
60 min). The differences in the titers between early (5
min) and late (60 min) infectivity of TGEV PUR46,
HAD3, and TGEV Miller were statistically significant
(with p < 0.05). The higher titers of TGEV PUR46 show
that this virus strain is more cell culture adapted than
the Miller strain. The early infectivity (5 min adsorption
time) of HAD3 is about 22.6% of the value for TGEV
PUR46 at this time point (with p = 0.014). However, the
late infectivity (60 min) of HAD3 is about 42.2% of the
value for TGEV PUR46 (with p = 0.021). This higher
difference between TGEV PUR46 and HAD3 in early
infectivity could be explained by the additional use of
sialic acids for adsorption by TGEV PUR46. At short
adsorption times, the importance of sialic acid binding
for infectivity is more pronounced than at longer
adsorption times when binding to the cellular receptor
pAPN compensated this phenomenon.
Reduction of TGEV infectivity by porcine intestinal mucins
To find out if the sialic acid binding activity of the
TGEV S protein can be inhibited by porcine intestinal
mucins which are rich in sialic acids we performed a
plaque assay after incubation of TGEV PUR46 with
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Figure 3 Comparison of early and late infectivity between TGEV PUR46, HAD3 and TGEV Miller. The infectious titers of TGEV PUR46,
HAD3 and TGEV Miller were calculated at adsorption times of 5, 20 and 60 min, respectively. Infectivity was expressed in plaque forming units
per ml (PFU/ml). Prior to infection, ST cells were incubated with either PBS (1, 4, 5) or PBS containing 50 mU of neuraminidase (2, 3, 6).
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Figure 4 Mucin-dependent infection of TGEV PUR46.P r i o rt o
infection, TGEV PUR46 was treated with the indicated mucin
concentrations for 30 min at room temperature. After a 5 min
adsorption time of the virus-mucin-mixture a plaque assay was
performed. Plaque reduction by mucin treatment was calculated
out of 2 independent experiments with quadruplicates. Standard
deviations are indicated. Significant differences are marked with an
asterisk (*, p-value < 0.05).
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rial and methods section. Figure 4 shows that TGEV
infectivity was inhibited by the mucin in a concentration
dependent manner. Preincubation of the parental virus
with 5 mg mucin/ml reduced its infectivity by 62%
when the virus adsorption time was 5 min. Previous stu-
dies have shown that binding to these porcine intestinal
mucins inhibited hemagglutination by TGEV [16]. Thus,
sialic acid binding by the TGEV S protein appears to be
inhibited by interaction with the tested mucin.
Conclusions
From these results, the picture arises that coronaviruses
have developed different strategies to make use of the
sialic acid binding activity. These coronaviruses can be
differentiated in three distinct groups. TGEV PUR46 as
a representative of the first group recognizes pAPN so
efficiently that the contribution of the sialic acid binding
activity to the infection of cultured cells has remained
unrecognized so far. Binding to pAPN is independent
from sialic acids. It even appears to be more efficient
when less sialic acid is present on pAPN itself [5]. Inter-
action with pAPN appears to be a slower process com-
pared to sialic acid binding. Thus, effects produced by
sialic acid binding can be recognized at short adsorption
times when pAPN binding is still incomplete. Only by
reducing the adsorption time we could show that the
binding to sialoglycoconjugates on the cell surface
increases the efficiency of TGEV PUR46 to infect cul-
tured cells. For this strain the sialic acid binding activity
may be required only to survive under unfavorable con-
ditions as encountered in the intestinal tract. Interest-
ingly, the Miller strain of TGEV did not show this
significant difference in the infection efficiency between
long and short adsorption times on neuraminidase-trea-
ted cells that was observed with the Purdue strain.
There appear to be gradual differences in the impor-
tance of the sialic acid binding activity for different
TGEV strains. The Miller strain of TGEV resembles
IBV in its dependence on the sialic acid binding activity.
These two viruses represent the second group of coro-
naviruses concerning their sialic acid binding activity.
Pre-treatment of various cell types with neuraminidase
has been shown to reduce the sensitivity to infection by
different strains of IBV [14,15]. A protein receptor has
so far not been identified for this avian coronavirus. The
presence of such a receptor cannot be excluded. The
third group of coronaviruses with sialic acid binding
activity is represented by viruses like bovine coronavirus
(BCoV) and human coronavirus OC43 (HCoV-OC43)
[17,18]. These viruses resemble influenza C virus not
only because of their preference for N-acetyl-9-O-acetyl-
neuraminic acid but also because they contain an acety-
lesterase that functions as a receptor-destroying enzyme.
T h ep r e s e n c eo ft h i se n z y m ea n dt h ep r e f e r e n c ef o ra
less common type of sialic acid are consistent with a
higher affinity for the respective type of sialic acid. On
the other hand, IBV which lacks a receptor-destroying
enzyme requires a larger amount of sialic acid on the
cell surfaces than do Sendai virus or influenza viruses
and thus has a lower affinity for sialic acid than the lat-
ter viruses which contain a neuraminidase as a receptor-
destroying enzyme [14]. These three groups of corona-
viruses with sialic acid binding activity may represent
different stages in an evolutionary process of using sialic
acid for infection: i, acquisition of a sialic acid binding
activity for increasing the efficiency of infection under
unfavorable conditions (TGEV-Purdue); ii, modulation
of the binding activity to exploit sialic acid as a general
receptor determinant for attachment to target cells
(TGEV-Miller, IBV); iii, further increase of the attach-
ment efficiency by acquiring an enzyme that inactivates
sialoglycoconjugates that prevent the spread of infection
(BCoV, HCoV-OC43). Coronaviruses are characterized
by one of the highest recombination frequencies among
RNA viruses. In this way, they can acquire new proper-
ties by recombination events. An ancestral coronavirus
might have had only a single receptor binding activity e.
g. to a protein receptor and therefore only a single
organ tropism e.g. the respiratory tract. By recombina-
tion events this virus could have acquired a sialic acid
binding activity. Thus, such a virus should have a broa-
dened tissue tropism e.g. additionally for the intestinal
tract and increased chances to survive. As in the case
for TGEV (with gradually differences), for such a virus
the sialic acid binding activity may be an accessory func-
tion that renders the virus more efficient. Through
further recombination events a receptor-destroying
enzyme could have been acquired and a higher binding
affinity to sialic acids could have been evolved. Such a
virus, like BCoV, resembles influenza viruses. The gene
for the receptor-destroying enzyme could have been
incorporated in the coronavirus genome during coinfec-
tions of the same cell with coronaviruses and influenza
viruses.
Materials and methods
Cell lines and virus strains
ST (swine testicular) and Vero cells were grown in Dul-
becco’s modified Eagle medium supplemented with fetal
calf serum (10% for ST, 5% for Vero cells).
The Purdue strain of TGEV (PUR46-MAD) [19] was
used throughout this study. Stock virus was propagated
on ST cells. After incubation for 20 to 24 h at 37°C, the
supernatant was harvested, clarified by centrifugation,
and stored at -80°C after the addition of 1% fetal calf
serum. The hemagglutination deficient mutant HAD3
(point mutation in the S protein at position 209 (Leu-
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[8]. Mutants m10 (deletion of 4 amino acids at position
146-149), and m8 (point mutation at amino acid 147
(Cys-Arg)) originally derived from the TGEV Purdue-
115 strain [6,7]. The Miller strain of TGEV [12] was
harvested after incubation for 48 h at 37°C on ST cells.
Propagation of the Beaudette strain of IBV on Vero cells
has been described recently [14].
Neuraminidase treatment
Prior to infection, cells were either treated with 200 μln e u r -
aminidase from Clostridium perfringens, type V (Sigma-
Aldrich, St. Louis, Missouri, USA) diluted in PBS, or mock-
treated, for 1 h at 37°C. For comparison between all tested
viruses a concentration of 250 mU/ml was used. To com-
pare the effect of different neuraminidase concentrations on
the infection by TGEV PUR46, the neuraminidase was used
in a concentration range of 50 mU/ml to 1.5 U/ml.
Plaque reduction assay for TGEV and TGEV mutants
The effect of desialylated cells on TGEV infection was
analyzed by a plaque assay [8]. ST cells were either trea-
ted with neuraminidase (see above), or mock-treated, for
1 h at 37°C. After washing, the cells were infected with
TGEV PUR46, TGEV mutants HAD3, m10, and m8, or
TGEV Miller. The reduction of plaques by neuramini-
dase treatment was calculated as a mean value out of 4
(3 for TGEV Miller) independent experiments.
Plaque reduction assay for IBV Beaudette
The Plaque reduction assay for IBV Beaudette was per-
formed on Vero cells as described previously [20]. The
plaque reduction was calculated as a mean value out of
3 independent experiments.
Mucin treatment
Virus was diluted in medium and incubated with differ-
ent concentrations of porcine intestinal mucin (0, 1, 2.5,
5 mg/ml) for 30 min at room temperature [16]. ST cells
were washed and incubated for 5 min at 37°C with
t h e s es a m p l e s .S u b s e q u e n t l y ,ap l a q u ea s s a yw a sp e r -
formed as described above. Plaque reduction by mucin
treatment was calculated as a mean value out of 2 inde-
pendent experiments with quadruplicates.
Calculation methods
P-values were calculated in Microsoft Office Excel 2007
by using the student’s t-test (single sided, type one). P <
0.05 was considered to indicate a statistically significant
difference.
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